Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19959781 | 0.92 | NPSR1 (0.36) | NPSR1 | |
| SCHEMBL19959825 | 0.92 | NPSR1 (0.32) | NPSR1 | |
| SCHEMBL19959820 | 0.91 | NPSR1 (0.36) | NPSR1 | |
| SCHEMBL19959776 | 0.88 | SMN1; SMN2 (0.35) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL19959864 | 0.88 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL19959794 | 0.87 | CYP2C9 (0.35) | MEN1NPC1ALDH1A1RAB9AKMT2A | |
| SCHEMBL19959863 | 0.87 | EGFR (0.32) | — | |
| SCHEMBL19959909 | 0.86 | USP2 (0.31) | ALDH1A1 | |
| SCHEMBL19959912 | 0.85 | NPSR1 (0.34) | ALDH1A1NPSR1 | |
| SCHEMBL19965897 | 0.85 | CYP2C9 (0.35) | MEN1NPC1ALDH1A1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10700289-B2 | Heterocyclic compound and organic light emitting element comprising same | LG CHEM, LTD. (KR) | 2020-06-30 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | LG CHEM, LTD. (KR) | 2018-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180076395-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT EMITTING ELEMENT COMPRISING SAME | CRY1, CRY2, PER2 | MEN1 885/4885NPC1 3974/4885ALDH1A1 750/4885 |
| US-10700289-B2 | Heterocyclic compound and organic light emitting element comprising same | CRY1, CRY2, PER2 | MEN1 885/4885NPC1 3974/4885ALDH1A1 750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.